VIR News and Press, Vir Biotechnology Inc. From 01/25/23

Vir Biotechnology ( NASDAQ: VIR ) announced on Wednesday the planned retirement of CEO George Scangos, effective April 3, 2023. Industry veteran Marianne De Backer has been named as Scangos' successor, effective April 3, 2023. De Backer, who currently serves as EVP, Head of Pharma...

– Dr. De Backer to assume CEO role on April 3, 2023 – – Upon his retirement as CEO, Dr. Scangos will transition to an advisory role through June 2, 2023 and will continue providing strategic counsel to Vir as a member of the Board of Directors ȁ...

Turning a $100 investment into $1,000 in five years isn't easy. Doing so requires a substantial compound annual growth rate (CAGR) exceeding 58%. You're not likely to see such a rate among value stocks, which for all their consistency rarely grow at that pace. Two companies where I see that k...

Summary Pharmaceuticals and biotechnology have the best value and quality scores in the sector. Healthcare providers are close to their historical baseline in valuation and quality. Fast facts on GNOM. 10 stocks cheaper than their peers in January. This monthly article...

Summary Vir Biotechnology is a commercial-stage immunology company that bases its activity on infectious disease prevention. The agreement with GSK made it possible to obtain large revenues and profits in 2022. A good pipeline allows us to assume high growth in the coming years. ...

Summary Alnylam's fourth quarter product revenue was more or less as expected, with a faster/better-than-expected pace of switching between Onpattro and Amvuttra and further patient growth in Oxlumo and Givlaari. Investors will have multiple clinical read-outs to anticipate this year, i...

Summary Today, I explain why I've taken a position in VIR, including going over its pipeline, partners, and anticipated milestones. I then look at the company's valuation and cash position as well as Seeking Alpha's quant ratings. After considering the risks, I think this is one of ...

– Critical Phase 2 readouts anticipated in 2023 for three advanced programs – hepatitis B, hepatitis D and influenza – – Strong balance sheet expected to fund Vir’s robust portfolio through major inflection points with the flexibility to evaluate...

Summary I've conducted a study of dozens of different value ratios. I outline my method here and present my results. I discuss value ratios in general, outlining what periods you should use and explaining why some ratios use price and others use enterprise value. The most effective ...

SAN FRANCISCO, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it has achieved the target enrollment of approximately 3,000 participants in the groundbreaking Phase 2 PENINSULA ( P rev E ntio N of I ll N es S ...